Clinical analysis of recombinant activated factor VIIa for 18 patients with severe bleeding / 中华血液学杂志

ABSTRACT

<p><b>OBJECTIVE</b>To find a kind of quick and effective haemostasis to decrease the mortality of severe bleeding.</p><p><b>METHODS</b>18 severe bleeding patients with different cause received recombinant activated factor VIIa (rFVIIa) were analyzed retrospectively.</p><p><b>RESULTS</b>Of total 18 cases with severe bleeding, 13 cases cured, 3 cases were effective, 2 cases ineffective. The total clinical effective rate is 88.89%. After using rFVIIa, the PT, APTT and fibrinogen level of 6 DIC patients returned to normal within 12 hours; 13 patients whose the amount of bleeding can be evaluated stopped bleeding quickly. The fastest onset time was 10 min.</p><p><b>CONCLUSION</b>rFVIIa can stanch severe bleeding for a variety of reasons rapidly and effectively, including coagulopathy, thrombocytopenia, and obstetric hemorrhage. Application of rFVIIa may decrease mortality, when conventional treatment is not valid.</p>